Navigation Links
NeurogesX Reports Fourth Quarter and Year-End 2008 Results
Date:3/20/2009

Qutenza(TM) Receives Positive Committee Recommendation in European Union

Corporate Highlights:

- CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain

- Qutenza NDA accepted for review by U.S. FDA for PHN

Upcoming 2009 Milestones:

- European commercial partnership for Qutenza anticipated first half of 2009

- European Commission decision on MAA for Qutenza for the treatment of peripheral neuropathic pain in non-diabetic adults alone or in combination with other medicinal products for pain anticipated first half of 2009

- FDA PDUFA date of August 16, 2009 for Qutenza NDA to manage pain associated with PHN

SAN MATEO, Calif., March 20 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the fourth quarter and full year ended December 31, 2008 and provided an update on recent developments.

During 2008, NeurogesX continued to make significant progress on the regulatory front in the United States and Europe. In October 2008, the Company submitted a new drug application (NDA) on schedule to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Qutenza for the management of pain associated with postherpetic neuralgia (PHN). In December 2008, the NDA was accepted by the FDA for review, resulting in a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

Regarding the European regulatory process for Qutenza, on March 19, 2009, the Committee for Medicinal Products for Hu
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
2. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
3. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
4. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
5. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
6. The NewsHour With Jim Lehrer Reports From South Africa on Renewed Efforts to Combat HIV/AIDS and Tuberculosis
7. Medical symposium highlights importance of case reports -- patient stories in modern medicine
8. Secova Reports Healthcare Provisions In The Stimulus Bill
9. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
10. Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results
11. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Glens Markets Adds Discounted Generic Drug Program 49508 1Glens Markets Adds Discounted Generic Drug Program 49508 2Glens Markets Adds Discounted Generic Drug Program 49508 3Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 49504 1Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 49504 2Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 49504 3Bicycle Helmet Laws For Kids Effective But Not Yet the Norm 49504 4Brain Imaging Study Sheds Light on Fibromyalgia 49502 1